Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC), 13123-13124 [2017-04618]

Download as PDF asabaliauskas on DSK3SPTVN1PROD with NOTICES Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices and insufficient levels of evidence to the following: ‘‘Data sets classified as sufficient are those that include human and/or animal studies conducted using standardized protocols and that provide complete descriptions of the exposure conditions and study findings. Data sets classified as limited are those that include human and/or animal studies conducted using non-standardized protocols or that provide incomplete descriptions of the exposure conditions or study findings. Data sets classified as insufficient are those that include human and/or animal studies conducted using nonstandardized protocols and that provide incomplete descriptions of the exposure conditions and study findings. Data sets that receive the insufficient ranking will not be used as the basis for the NIOSH skin notation.’’ Evaluation of dose-related effects in studies with limited or insufficient evidence, mechanistic data, and analogous chemical properties may be factored into the classification scheme for determining the level of evidence for identified studies. Data sets that provide insufficient evidence will not be used as the basis for the NIOSH skin notation but, in some cases, may provide information to support or contradict evidence for the skin notation. For data sets with conflicting findings, an overall determination based on the body of evidence will be developed by evaluating data adequacy, reliability and relevance, and assessing each study’s quality of evidence. The studies with the best quality and validity to support the notation are identified and cited in the individual Skin Notation Profile documents. NIOSH seeks comments on proposed changes as described above. DATES: Comments must be submitted on or before April 10, 2017. ADDRESSES: You may submit comments, identified by CDC–2017–0017 and docket number NIOSH 153–D, by any of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998. Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2017–0017; NIOSH 153–D]. All relevant comments received will be posted without change to www.regulations.gov, including any personal information provided. For access to the docket to read background VerDate Sep<11>2014 17:43 Mar 08, 2017 Jkt 241001 documents or comments received, go to www.regulations.gov. For access to the original docket [NIOSH–153] to view background documents or comments received, go to https://www.cdc.gov/ niosh/docket/archive/docket153.html. All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226–1998. FOR FURTHER INFORMATION CONTACT: Naomi Hudson or G. Scott Dotson, NIOSH, Education and Information Division, Robert A. Taft Laboratories, 1190 Tusculum Ave, MS C–32, Cincinnati, OH 45226, email: iuz8@ cdc.gov or fya8@cdc.gov. In 2009, NIOSH published Current Intelligence Bulletin 61—A Strategy for assigning New NIOSH Skin Notations [NIOSH 2009–147; https://www.cdc.gov/niosh/ docs/2009-147/pdfs/2009-147.pdf]. The CIB presents a strategic framework that is a form of hazard identification that ensures that the assigned skin notations reflect the contemporary state of scientific knowledge, provides transparency behind the assignment process, communicates the hazards of chemical exposures of the skin, and meets the needs of health professionals, employers, and others interested in protecting workers from chemical contact with the skin. Published Skin Notation Profile documents are available at https://www.cdc.gov/niosh/ topics/skin/skin-notation_profiles.html. SUPPLEMENTARY INFORMATION: Frank Hearl, Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2017–04628 Filed 3–8–17; 8:45 am] 13123 1:00 p.m.–5:00 p.m., EDT, April 11, 2017 (Closed). PLACE: Teleconference. STATUS: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. MATTERS FOR DISCUSSION: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Cooperative Agreement on Global Occupational Health with the World Health Organization (WHO)’’, RFA– OH17–1701. CONTACT PERSON FOR MORE INFORMATION: Nina Turner, Ph.D., Scientific Review Officer, NIOSH, CDC, 1095 Willowdale Road, Mailstop G905, Morgantown, West Virginia 26506, Telephone: (304) 285–5976. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. TIME AND DATE: Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–04626 Filed 3–8–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4163–18–P Centers for Disease Control and Prevention DEPARTMENT OF HEALTH AND HUMAN SERVICES Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC) Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to RFA–OH17–1701, Cooperative Agreement on Global Occupational Health with the World Health Organization (WHO). PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee: Time and Date: 8:30 a.m.–3:00 p.m., EDT, April 20, 2017. Place: CDC, Building 19, Auditorium B3, 1600 Clifton Road NE., Atlanta, Georgia 30329. Status: Open to the public, limited only by the seating and phone lines available. The meeting room accommodates approximately 60 people. Advance registration for in- E:\FR\FM\09MRN1.SGM 09MRN1 13124 Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices asabaliauskas on DSK3SPTVN1PROD with NOTICES person participation is required by April 6, 2017. The public is welcome to participate during the public comment period, which is tentatively scheduled from 2:40 p.m. to 2:45 p.m. This meeting will also be available by teleconference. Please dial (888) 324– 9970 and enter code 32077657. Purpose: The Advisory Committee to the Director, CDC, shall advise the Secretary, HHS, and the Director, CDC, on policy and broad strategies that will enable CDC to fulfill its mission of protecting health through health promotion, prevention, and preparedness. The committee recommends ways to prioritize CDC’s activities, improve results, and address health disparities. It also provides guidance to help CDC work more effectively with its various private and public sector constituents to make health protection a practical reality. Matters for Discussion: The Advisory Committee to the Director will receive updates from the State, Tribal, Local and Territorial Subcommittee; the Health Disparities Subcommittee, the Global Workgroup, and the Public Health—Health Care Collaboration Workgroup, as well as an update from the Acting CDC Director. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Sarah Wiley, MPH, Designated Federal Officer, ACD, CDC, 1600 Clifton Road NE., M/S D–14, Atlanta, Georgia 30329. Telephone (404) 498–6482, Email: ACDirector@cdc.gov. The deadline to register for in-person attendance at this meeting is April 6, 2017. To register, please send an email to ACDirector@ cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 2017–04618 Filed 3–8–17; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 17:43 Mar 08, 2017 Jkt 241001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier: CMS–1984–14] Agency Information Collection Activities: Proposed Collection; Comment Request Centers for Medicare & Medicaid Services, Department of Health and Human Services. ACTION: Notice. AGENCY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. DATES: Comments must be received by May 8, 2017. ADDRESSES: When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways: 1. Electronically. You may send your comments electronically to https:// www.regulations.gov. Follow the instructions for ‘‘Comment or Submission’’ or ‘‘More Search Options’’ to find the information collection document(s) that are accepting comments. 2. By regular mail. You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number llll, Room C4–26– 05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. SUMMARY: PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following: 1. Access CMS’ Web site address at https://www.cms.gov/Regulations-andGuidance/Legislation/ PaperworkReductionActof1995/PRAListing.html. 2. Email your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov. 3. Call the Reports Clearance Office at (410) 786–1326. FOR FURTHER INFORMATION CONTACT: Reports Clearance Office at (410) 786– 1326. SUPPLEMENTARY INFORMATION: Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection’s supporting statement and associated materials (see ADDRESSES). CMS–1984–14 Hospital Facility Cost Report Under the PRA (44 U.S.C. 3501– 3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term ‘‘collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice. Information Collection 1. Type of Information Collection Request: Reinstatement of a previously approved collection; Title of Information Collection: Hospital Facility Cost Report; Use: Providers of services participating in the Medicare program are required under §§ 1815(a), 1833(e), and 1861(v)(1)(A) of the Social Security Act (42 U.S.C. 1395g) to submit annual information to determine costs for health care services rendered to Medicare beneficiaries. In addition, E:\FR\FM\09MRN1.SGM 09MRN1

Agencies

[Federal Register Volume 82, Number 45 (Thursday, March 9, 2017)]
[Notices]
[Pages 13123-13124]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04618]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee to the Director (ACD), Centers for Disease 
Control and Prevention (CDC)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting of the aforementioned 
committee:
    Time and Date: 8:30 a.m.-3:00 p.m., EDT, April 20, 2017.
    Place: CDC, Building 19, Auditorium B3, 1600 Clifton Road NE., 
Atlanta, Georgia 30329.
    Status: Open to the public, limited only by the seating and phone 
lines available. The meeting room accommodates approximately 60 people. 
Advance registration for in-

[[Page 13124]]

person participation is required by April 6, 2017. The public is 
welcome to participate during the public comment period, which is 
tentatively scheduled from 2:40 p.m. to 2:45 p.m. This meeting will 
also be available by teleconference. Please dial (888) 324-9970 and 
enter code 32077657.
    Purpose: The Advisory Committee to the Director, CDC, shall advise 
the Secretary, HHS, and the Director, CDC, on policy and broad 
strategies that will enable CDC to fulfill its mission of protecting 
health through health promotion, prevention, and preparedness. The 
committee recommends ways to prioritize CDC's activities, improve 
results, and address health disparities. It also provides guidance to 
help CDC work more effectively with its various private and public 
sector constituents to make health protection a practical reality.
    Matters for Discussion: The Advisory Committee to the Director will 
receive updates from the State, Tribal, Local and Territorial 
Subcommittee; the Health Disparities Subcommittee, the Global 
Workgroup, and the Public Health--Health Care Collaboration Workgroup, 
as well as an update from the Acting CDC Director.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Sarah Wiley, MPH, Designated 
Federal Officer, ACD, CDC, 1600 Clifton Road NE., M/S D-14, Atlanta, 
Georgia 30329. Telephone (404) 498-6482, Email: ACDirector@cdc.gov. The 
deadline to register for in-person attendance at this meeting is April 
6, 2017. To register, please send an email to ACDirector@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 2017-04618 Filed 3-8-17; 8:45 am]
 BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.